This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

NCT07162571 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
17
Enrollment
OTHER_GOV
Sponsor class

Conditions

Interventions

Sponsor

Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology